ARTA
JAZZ icon

A.R.T. Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

A.R.T. Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,158
Closed -$362K – 1487
2018
Q3 		$362K Buy
+2,158
New +$371K 0.02% 973
2018
Q1 		– Sell
-9,758
Closed -$1.31M – 1629
2017
Q4 		$1.31M Buy
+9,758
New +$1.35M 0.06% 519
2017
Q3 		– Sell
-8,600
Closed -$1.34M – 1492
2017
Q2 		$1.34M Buy
8,600
+5,400
+169% +$826K 0.07% 397
2017
Q1 		$464K Sell
3,200
-37,400
-92% -$4.87M 0.02% 841
2016
Q4 		$4.43M Buy
40,600
+38,300
+1,665% +$4.27M 0.26% 75
2016
Q3 		$279K Sell
2,300
-26,980
-92% -$3.64M 0.09% 369
2016
Q2 		$4.14M Buy
29,280
+25,600
+696% +$3.77M 0.21% 115
2016
Q1 		$480K Sell
3,680
-400
-10% -$49.8K 0.02% 873
2015
Q4 		$573K Buy
+4,080
New +$565K 0.03% 804
2015
Q3 		– Sell
-7,502
Closed -$1.32M – 1469
2015
Q2 		$1.32M Sell
7,502
-3,554
-32% -$638K 0.04% 616
2015
Q1 		$1.91M Buy
+11,056
New +$1.9M 0.07% 410
2014
Q1 		– Sell
-3,562
Closed -$450K – 1444
2013
Q4 		$450K Buy
+3,562
New +$369K 0.02% 811

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

A.R.T. Advisors's JAZZ Position: Q4 2018 in Review

A.R.T. Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 2,158 shares — an estimated $362K sold.

A.R.T. Advisors first reported a position in JAZZ in Q4 2013 and held it in 12 quarters. The position peaked at $4.43M in Q4 2016. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

  • A.R.T. Advisors reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • A.R.T. Advisors sold 2,158 Jazz Pharmaceuticals shares in Q4 2018, an estimated $362K.
  • A.R.T. Advisors first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 12 quarters.
  • A.R.T. Advisors's Jazz Pharmaceuticals position peaked at $4.43M in Q4 2016.
  • 417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on A.R.T. Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.